On Thursday, GlaxoSmithKline plc (ADR) (NYSE:GSK)’s shares inclined 0.26% to $42.25.
GlaxoSmithKline (GSK) declared that the U.S. Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) voted for a Category B recommendation for meningococcal group B vaccination, counting BEXSERO® (Meningococcal Group B Vaccine), in individuals aged 16 to 23 (with a preferred age of 16-18). This recommendation means that the decision to vaccinate against meningococcal group B will be made by qualified healthcare professionals, based on individual patient risk assessment. BEXSERO®
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, counting vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, counting respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas.
Sanchez Energy Corp (NYSE:SN)’s shares dropped -1.39% to $9.20.
Sanchez Energy Corp (SN) declared the appointment of Jaime Brito as Senior Vice President of Investor Relations, effective June 15, 2015.
Mr. Brito brings more than 20 years of financial and operating experience in the energy sector. Prior to this appointment, Mr. Brito served in various operational roles at Rosetta Resources Inc. counting Forecasting, Regulatory Affairs, GIS Systems and Supply Chain Administration. He has also served in several investor relation positions while at Mariner Energy, Inc. and Halliburton. Mr. Brito earned Bachelor of Science and Master of Science degrees in Civil and Environmental Engineering from Massachusetts Institute of Technology and a Master of Business Administration from Rice University.
Sanchez Energy Corporation, an independent exploration and production company, focuses on the acquisition, exploration, and development of unconventional oil and natural gas resources in the onshore U.S. Gulf Coast. It has about 226,000 net leasehold acres in the oil and condensate, or black oil and volatile oil, windows of the Eagle Ford Shale in South Texas; and about 69,000 net leasehold acres in the Tuscaloosa Marine Shale in Mississippi and Louisiana.
At the end of Thursday’s trade, Novavax, Inc. (NASDAQ:NVAX)‘s shares dipped -1.09% to $10.88.
Novavax, Inc. (NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, recently declared the appointment of Gail K. Boudreaux to its Board of Directors.
Ms. Boudreaux most recently served as the Executive Vice President of UnitedHealth Group from May 2008 until February 2015 and was the Chief Executive Officer of UnitedHealthcare from January 2011 to November 2014. Her extensive experience comprises more than 30 years of service across a broad spectrum of health care operations. Ms. Boudreaux is presently a director of Zimmer Holdings, Inc. and Xcel Energy Inc. and a trustee of Dartmouth College. Ms. Boudreaux holds a Master of Business Administration degree in finance and health care administration from the Columbia Business School and a bachelor’s degree in psychology from Dartmouth College. She has been honored as one of Fortune’s 50 Most Powerful Women in American Business for the last six years and was recognized by Modern Healthcare as one of the Top 25 Women in Healthcare.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline comprises respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase II clinical trials, in addition to pediatric respiratory syncytial virus candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase I clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, in addition to combination respiratory vaccine candidate, which is pre-clinical trial; and seasonal influenza vaccine candidate that is Phase III clinical trial, in addition to rabies G protein vaccine candidate, which is in Phase 1/2 clinical trial.
SLM Corp (NASDAQ:SLM), ended its Thursday’s trading session with 0.71% gain, and closed at $9.97.
Sallie Mae (SLM), the nation’s saving, planning and paying for College Company, declared a 2015 third-quarter dividend on its Preferred Stock Series A of 6.97 percent, or $0.87125 per share. The dividend will be paid on July 30, 2015, to stockholders of record at the close of business on July 20, 2015.
On March 31, 2015, Sallie Mae had about 3.3 million shares of Preferred Stock Series A outstanding.
SLM Corporation, together with its auxiliaries, operates as a saving, planning, and paying for education company in the United States. The company offers private education loans to students and their families. It also provides banking products, such as high yield savings accounts, money market accounts, and certificates of deposits; and operates a consumer savings network that offers financial rewards on everyday purchases to assist families save for college. SLM Corporation was founded in 1972 and is headquartered in Newark, Delaware.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
